Abstract
The relationship between apoptosis, apoptosis regulatory proteins, cell proliferation and human papillomavirus infection during various phases of tumor progression in the uterine cervix was studied. Apoptosis was defined by morphological criteria and the TUNEL assay. Expression of p53, bcl-2, bax, cyclin D1, Ki 67 and E6 protein was evaluated by immunocytochemistry. Presence of mutant p53 was detected using a mutant specific ELISA. Type of HPV infection was determined by PCR using type specific primers. Apoptosis showed significant negative correlation with increasing histological abnormality (p=0.0005). Higher tumor cell proliferation was associated with increasing histological abnormality (p=0.001 for Ki 67 and cyclin D1). There was significant correlation between histological grade and immunoreactivity of p53 (p=0.0001 ) and bcl-2 (p=0.0002). However, mutant p53 was expressed by only 12 of the 230 samples. Expression of bax and the bax/bcl-2 ratio showed an inverse correlation to histological grade (p=0.0003 and 0.0001, respectively). There was also an inverse correlation between extent of apoptosis and immunoreactivity of p53 (p=0.0001) and bcl-2 (p=0.0001). A significant positive correlation between expression of the bax protein and apoptosis was evident (p=0.0001). HPV infection significantly correlated to the extent of histological abnormality (p=0.0001). High risk HPV-E6 protein also showed this significant correlation (p=0.0002). There was an inverse correlation between apoptosis and HPV infection (p=0.0002). High risk HPV infection was associated with decreased apoptosis and also increased human cell proliferation. Lowest levels of bax/bcl-2 ratio was also associated with HPV 16 and 18 infection (p=0.0001). Modulation of apoptosis and apoptotic regulatory proteins by high risk HPV infection may be an important factor in the development of cervical cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802, 1995.
Cotter TG, Samali A: Oncogenes, apoptosis and cancer. Forum Trends Exp Clin Med 7:4–17, 1997.
Furuya H, Yaboshita H, Noguchi M, et al: Apoptosis and cell growth fraction in normai, dysplastic and neoplastic squamous epithelium of uterine cervix. Nippon Rinsha, 54:1916–1921, 1996.
Guchelaar HJ, Vermes A, Vermes I, et al: Apoptosis: Molecular mechanisms and implications for cancer chemotherapy. Pharmacy World and Science, 19:119–125, 1997.
Isacson C, Kessis TD, Hedrick L, et al: Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 56:669–674, 1996.
Jayant K, Rao RS, Nene BM, et al: Improved stage at diagnosis of cervical cancer with increased cancer awareness in a rural Indian population. Int J Cancer 63:161–163, 1995.
Kagawa S, Fujiwara T, Hizuta A, et al: P53 expression overcomes p21 (WAF1/ CIP1)-mediated G-1 arrest. Oncogene 15:1903–1909, 1997.
Kerr JFR, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 73:2013–2026, 1994.
Kesari AL, Chellam VG, Nair PP, et al: Expression of the antiapoptotic protein bcl-2 is not dependent on the tumor suppressor protein p53 in Indian breast carcinoma. Pathobiol 65:108–112, 1997.
Kurvinen K, Tervahauta A, Syrjanen S, et al: The state of the p53 gene in human papillomavirus (HPV)- positive and HPV-negative genital precancer lesions and carcinomas as determined by single-strand conformation polymorphism analysis and sequencing. Anticancer Res 14:177–181, 1994.
Lakshmi S, Nair BS, Jayaprakash PG, et al: P53 protein and tumorigenesis in the uterine cervix. Gen Diag Pathol 142:281–287, 1997.
Lane DP: p53, guardian of the genome. Nature 358:15–16, 1992.
Lechner MS, Mack DH, Finicle AB, et al: Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J 11:3045–3052, 1992.
Liang XH, Volkmann M, Klein R, et al: Co-localization of the tumor suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. Oncogene 8:2645–2652, 1993.
Matlashewski G: Human papillomavirus update, 15th Annual Intemational Papillomavirus Workshop, Gold Coast Australia, 1996.
Mietz JA, Unger T, Huibregtse JM, et al: The transcriptional transactivation function of wild type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11:5013–5020,1992.
Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799–1805, 1994.
Nelson WG, Kastan MB: DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815–1823, 1994.
Pan H, Yin C, Van-Dyke T: Apoptosis and cancer mechanisms. Cancer Surveys 29:305–327, 1997.
Picksley SM, Lane DP: p53 and Rb, their cellular roles. Curr Opin Cell Biol 6:853–858, 1994.
Pillai MR, Kesari AL, Chellam VG, et al: Spontaneous programmed cell death in infiltrating duct carcinoma: association with p53, bcl-2, hormone receptors and tumor proliferation. Pathology Res Pract (in press). 1998.
Pillai R, Halabi S, McKalip A, et al: The Presence of Human Papillomavirus 16/18 E6, p53 and Bcl-2 protein in cervicovagina) smears from patients with invasive cervical cancer. Cancer Epidemiol, Biomark Prevent, 5:329–335, 1996.
Ravi D, Nalinakumari KR, Rajaram RS, et al. Expression of programmed cell death regulatory p53 and bcl-2 proteins in oral lesions. Cancer Letters 105:139–146, 1996.
Ravi D, Ramdas K, Mathew BS, et al: Angiogenesis during tumor progression in the oral cavity is related to reduced apoptosis and high tumor cell proliferation. Eur J Cancer Part I I, OralOncol (in press). 1998.
Reihsaus E, Kohler M, Kraiss S, et al: Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 5:137–145, 1990.
Sanchez-Perez AM, Soriano S, Clarke AR, et al: Disruption of the human papillomavirus type 16 E2 gene protects cervica! carcinoma cells from E2F-induced apoptosis. J General Virol 78:3009–3018, 1997.
Sheets E, Crum CP, Yeh J: Association between cervical neoplasia and apoptosis as detected by in situ nuclear labelling. Gynecol Oncol, 63:94–100, 1996.
Shibata DK, Arnheim N, Martin WJ: Detection of human papilloma virus in paraffin embedded tissue using the polymerase chain reaction. J Exp Med 167:225–230, 1988.
Shoji Y, Saegusa M, Takano Y, et al: Correlation of apoptosis with tumor cell differentiation, progression and HPV infection in cervical carcinoma. J Clin Pathol 49:134–138, 1996.
Sidransky D, Hollstein M: Clinical implications of the p53 gene. Annu Rev Med 47:285–301, 1996.
Srinivas G, Kusumakumary P, Nair MK, et al: BCL-2 protein and apoptosis in paediatric acute lymphoblastic leukaemia. Internat J Mol Med (in press), 1998.
Takahashi R: Role of p53 tumor suppressor gene and Fas I Apo1 in induction of apoptosis and differentiation of cancer cells. Leukemia 11:331–333, 1997.
Ting Y, Manos MM: Detection and typing of genital human papillomavirus, in PCR protocols: A Guide to Methods and Applications, New York, Academic Press, pp 356–367, 1990.
Wang TT: Differential effects of chemotherapeutic agents on bcl-2/bax apoptosis pathway in breast cancer cell. Proc Annu Meet Am Assoc Cancer Res 38:A769, 1997.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nair, P., Nair, M.K., Jayaprakash, P.G. et al. Decreased programmed cell death in the uterine cervix associated with high risk human papillomavirus infection. Pathol. Oncol. Res. 5, 95–103 (1999). https://doi.org/10.1053/paor.1999.0161
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1053/paor.1999.0161